Immunome, Inc.
IMNM
$27.20
$0.782.95%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -254.32M | -224.59M | -212.39M | -222.74M | -212.39M |
| Total Depreciation and Amortization | 3.42M | 2.98M | 2.96M | 2.77M | 2.61M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.21M | 36.89M | 33.75M | 48.11M | 52.35M |
| Change in Net Operating Assets | 1.89M | -11.79M | -15.23M | -13.16M | -21.26M |
| Cash from Operations | -208.79M | -196.50M | -190.92M | -185.03M | -178.68M |
| Capital Expenditure | -10.29M | -9.02M | -9.69M | -6.81M | -7.24M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -186.19M | 52.72M | 70.49M | 81.37M | -17.99M |
| Cash from Investing | -196.48M | 43.70M | 60.80M | 74.56M | -25.23M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 508.17M | 507.33M | 679.81M | 239.72M | 193.92M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -29.07M | -29.34M | -39.46M | -12.07M | -11.36M |
| Cash from Financing | 479.11M | 477.99M | 640.36M | 227.65M | 182.56M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 73.83M | 325.19M | 510.24M | 117.18M | -21.35M |